Myeloid Antigen Expression in Childhood Acute Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol

Abstract

The frequency of acute lymphoblastic leukemia (ALL) patients expressing myeloid antigens on their ALL cells varies between 5 and 36% in several different studies. The clinical relevance of myeloid antigen expression in childhood ALL is controversial. In Indonesian patients, no data were present. Therefore, in Yogyakarta, Indonesia, we analyzed 239 ALL patients who were immunophenotyped including myeloid markers (CD13, CD33, CD117, and/or cMPO). Myeloid antigen expression was found in 25% of patients. Expression of myeloid antigen in B-lineage leukemia was 27%, and in T-lineage leukemia, it was 18% (P = 0.15). No association was found between myeloid antigen expression and clinical or biological features. In the whole cohort of patients we did not find a significant association between myeloid antigen expression and survival, although leukemia-free survival at 3 years was higher in the myeloid-negative patients (73% ± 6%) compared to myeloid-positive patients (67% ± 8%). Interestingly, in T-ALL patients, expression of myeloid antigens was an independent adverse prognostic factor (hazard ratio: 3.26, 95% CI: 1.06-9.98, P = 0.04). Kaplan-Meier analysis for event-free survival was also significant (log rank P = 0.03) in this subgroup. In conclusion, in the Indonesian ALL population, in particular, myeloid antigen-expressing T-ALL patients had a higher chance of having induction failure.

Figure 1

Survival analysis of myeloid expression in overall childhood ALL, treated with Indonesia 2006 protocol. (a) Event-free survival with log rank P = 0.228 and (b) Leukemia-free survival with log rank P = 0.085.

Figure 2

Survival analysis of myeloid expression in B-lineage ALL, treated with Indonesia 2006 protocol. (a) Event-free survival with log rank P = 0.621 and (b) Leukemia-free survival with log rank P = 0.420.

Figure 3

Survival analysis of myeloid expression in T-lineage ALL, treated with Indonesia 2006 protocol. (a) Event free survival with log rank P = 0.028 (b) Leukemia free survival with log rank P = 0.001.